Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Reviva Pharmaceuticals Holdings, retaining the price target of $2.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Reviva Pharmaceuticals Holdings’ promising future. The company is preparing for a critical pre-NDA meeting with the FDA, expected before the end of 2025, which will provide clarity on the regulatory path for their schizophrenia treatment, brilaroxazine. A positive outcome from this meeting could pave the way for a New Drug Application submission by the second quarter of 2026, supported by encouraging Phase 2 and Phase 3 trial results, as well as additional study data.
Moreover, Reviva’s financial position appears stable with recent financing activities, including a $9 million equity raise and an additional $6.4 million from warrant exercises, extending their cash runway into 2026. The company’s recent presentations at major conferences, showcasing positive long-term efficacy and safety data for brilaroxazine, further reinforce the potential for successful market entry. These elements collectively underpin McCarthy’s optimistic outlook and Buy recommendation for Reviva’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -19.0% and a 29.78% success rate on recommended stocks.
In another report released on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.